Literature DB >> 22649135

[¹⁸F]Fluorodeoxyglucose positron emission tomography-guided therapy in metastatic adrenocortical carcinoma: an illustrative case.

Hubert H Chuang1, Ferhat Deniz, Kanishka Sircar, Camilo Jimenez, Carlos Rubin De Celis, Christopher G Wood, Mouhammed Amir Habra.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22649135      PMCID： PMC3434990          DOI： 10.1200/JCO.2011.40.6710

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  17 in total

Review 1.  Oncological applications of FDG PET imaging.

Authors:  D Delbeke
Journal:  J Nucl Med       Date:  1999-10       Impact factor: 10.057

2.  Early prediction of response to first-line therapy using integrated 18F-FDG PET/CT for patients with advanced/metastatic non-small cell lung cancer.

Authors:  Dae Ho Lee; Seok-Ki Kim; Ho-Young Lee; Sung Young Lee; Sun Hwa Park; Hyae Young Kim; Keon Wook Kang; Ji-Youn Han; Heung Tae Kim; Jin Soo Lee
Journal:  J Thorac Oncol       Date:  2009-07       Impact factor: 15.609

3.  Imaging of adrenal tumors using FDG PET: comparison of benign and malignant lesions.

Authors:  S Maurea; C Mainolfi; L Bazzicalupo; M R Panico; C Imparato; B Alfano; M Ziviello; M Salvatore
Journal:  AJR Am J Roentgenol       Date:  1999-07       Impact factor: 3.959

Review 4.  Adrenal cortical carcinoma.

Authors:  A P Dackiw; J E Lee; R F Gagel; D B Evans
Journal:  World J Surg       Date:  2001-07       Impact factor: 3.352

5.  Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.

Authors:  H Young; R Baum; U Cremerius; K Herholz; O Hoekstra; A A Lammertsma; J Pruim; P Price
Journal:  Eur J Cancer       Date:  1999-12       Impact factor: 9.162

6.  Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography.

Authors:  J J Erasmus; E F Patz; H P McAdams; J G Murray; J Herndon; R E Coleman; P C Goodman
Journal:  AJR Am J Roentgenol       Date:  1997-05       Impact factor: 3.959

7.  Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET.

Authors:  Gerald Antoch; Nina Saoudi; Hilmar Kuehl; Gerlinde Dahmen; Stefan P Mueller; Thomas Beyer; Andreas Bockisch; Jörg F Debatin; Lutz S Freudenberg
Journal:  J Clin Oncol       Date:  2004-11-01       Impact factor: 44.544

8.  The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.

Authors:  Isis Gayed; Thuan Vu; Revathy Iyer; Marcella Johnson; Homer Macapinlac; Nancy Swanston; Donald Podoloff
Journal:  J Nucl Med       Date:  2004-01       Impact factor: 10.057

9.  Indeterminate adrenal mass in patients with cancer: evaluation at PET with 2-[F-18]-fluoro-2-deoxy-D-glucose.

Authors:  G W Boland; M A Goldberg; M J Lee; W W Mayo-Smith; J Dixon; M M McNicholas; P R Mueller
Journal:  Radiology       Date:  1995-01       Impact factor: 11.105

10.  Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation.

Authors:  R L Wahl; K Zasadny; M Helvie; G D Hutchins; B Weber; R Cody
Journal:  J Clin Oncol       Date:  1993-11       Impact factor: 44.544
View more
  1 in total

1.  Impact of ¹⁸F-FDG PET/CT on the management of adrenocortical carcinoma: analysis of 106 patients.

Authors:  Satoshi Takeuchi; Aparna Balachandran; Mouhammed Amir Habra; Alexandria T Phan; Roland L Bassett; Homer A Macapinlac; Hubert H Chuang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-07-03       Impact factor: 9.236
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.